Hebrew University and TechforCann Europe Accelerator to Collaborate on Funding Medical Cannabis Research Companies Worldwide
Ryan Allway
January 14th, 2022
News
JERUSALEM, ISRAEL… January 14, 2022 — The Hebrew University of Jerusalem’s (HU) Technology Transfer Company, Yissum, together with the TechforCann Europe Accelerator, announces a strategic collaboration with TechforCann, Europe’s first medical cannabis tech accelerator, to fund startups around the world.
Researchers at HU’s Multidisciplinary Center for Cannabinoid Research, (MCCR) will serve as advisory board members, mentors, and potential candidates for the startups that are accepted into the TechforCann Europe Accelerator program. The HU Medical Cannabis online curriculum will also be available to international audiences through the accelerator platform. TechforCann will have access to a pipeline of innovative research projects that will benefit from the acceleration program. The parties will collaborate on licensing or co-development of new products.
HU’s MCCR, one of the world’s few cannabis incubators, conducts breakthrough research on cannabinoids, endocannabinoids, and medical cannabis. It focuses on solutions to address cancer, pain management, inflammation and stress management, immunity, metabolism, nano drug delivery, pharmaceutical chemistry, neuroscience, plant science and genetics.
TechforCann is the first accelerator to focus on medical cannabis technologies in Europe. The accelerator identifies and nurtures early-stage IP based companies with potential for exit/IPO. The hybrid acceleration program focuses on entrepreneurs who are solving challenges across the supply chain, with a focus on healthcare and biotech, digital health, precision agriculture, and new product technologies. Established by two Israel-based female co-founders Lilac Mandeles and Yona Cymerman –the TechforCannEU accelerator program allows entrepreneurs to reach milestones faster, with less error and expense, ultimately increasing their probability of commercial success.
“One of our major objectives at MCCR is to foster collaborations between our own teams and other groups worldwide who are conducting medical cannabis research,” said HU Prof. of Pharmacology Yossi Tam, MCCR director and head of the Obesity & Metabolism Laboratory. “A key priority is a cannabis-based synthetic active pharmaceutical ingredient (API) that may change people’s lives. For example, we have recently completed pre-clinical work with a synthetic derivative of cannabinoid-acid, demonstrating its efficacy in treating obesity, and we have a lot more research in the pipeline.”
“Partnering with such important and world-breaking institutions such as Yissum and the MCCR validates our goal of supporting early-stage IP based startups from around the world who are solving challenges across the medical cannabis supply chain,” says Lilac Mandeles, CEO of TechforCann. “We are excited to nurture and promote top-tier research that is currently being conducted, as well as offer our startups access to world-leading clinicians and researchers as well as cut the time to market for these remarkable innovations.”
For more information: www.techforcanneurope.com
About Yissum
Yissum is the technology transfer company of The Hebrew University of Jerusalem (HU). Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875+ patents globally; licensed over 1140+ technologies and has spun out more than 191 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and more. For more information, please visit www.yissum.co.il.
About the Hebrew University of Jerusalem
The Hebrew University of Jerusalem is Israel’s leading academic and research institution. Serving 23,000 students from 80 countries, it produces a third of Israel’s civilian research and is ranked 12th worldwide in biotechnology patent filings and commercial development. Faculty and alumni of the Hebrew University have won eight Nobel Prizes and a Fields Medal since 2000. The Hebrew University has 302 academic agreements with institutions in 44 countries; 78 competitive research grants from the European Research Council (ERC) since 2007; student exchange agreements with 56 institutions in 24 countries; 90 courses for the study of some 30 languages; 177 postdoctoral researchers from 26 countries; and an annual enrollment of approximately 2,000 students from 80 countries at the Rothberg International School. For more about the Hebrew University, see http://new.huji.ac.il/en.
About American Friends of the Hebrew University
American Friends of the Hebrew University (AFHU) is a national, not-for-profit organization based in the United States. AFHU is headquartered in New York and has six regional offices working in close partnership with the Hebrew University of Jerusalem. AFHU provides supporters, Hebrew University alumni and the general public with stimulating programs and events and organizes missions to Israel. The organization’s fundraising activities support scholarly and scientific achievement at the Hebrew University, create scholarships, new facilities and assist the university’s efforts to recruit outstanding new faculty. For more information, please visit http://www.afhu.org/.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Xtraction Services provides state-of-the-art, fully-automated, supercritical CO2 extraction machines with on-site staffing at no upfront cost, and a simple volume-based pricing model.
The Gluu is the first ever distribution platform serving the larger cannabis industry, linking together suppliers, manufacturers, reps, retailers and customers. If you sell products think of us as the B2B Amazon of the industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
